
    
      The purpose of this is study is to assess the efficacy of navigated laser treatment in
      reducing the number of anti-VEGF injections required to maintain visual gain obtained after
      Bevacizumab compared to Bevacizumab alone in patients with clinically significant macular
      edema (CSME).

      This will be prospective, active-controlled study using Bevacizumab (Genentech, South San
      Francisco CA) for intravitreal injections. Retinal photocoagulation will utilize the Navilas
      Laser System (OD-OS GmbH, Teltow, Germany), which is an approved indication for this device.
    
  